Coherus Oncology Inc (CHRS)

Cost of Revenue

$18.57M

TTM · Period ending: · USD

CHRS logo

CHRS Cost of Revenue

Latest reported$18.57M
CHRS TTM Cost of Revenue ($31.28M → $18.57M)
High-resolution chart · PNG

CHRS cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Coherus Oncology Inc Cost of Revenue — Trailing twelve months (TTM) (USD)
Period endingCost of Revenue (USD)
18,565,000
18,734,000
17,738,000
46,655,000
62,709,000
87,853,000
85,593,000
136,302,000
148,264,000
143,557,000
158,992,000
88,627,000
91,158,000
77,587,000
70,083,000
67,985,000
54,031,000
59,450,000
57,591,000
57,160,000
44,880,000
38,323,000
37,667,000
33,799,000
31,246,000
21,708,000
17,078,000
35,936,000
57,230,000
83,148,000
106,378,000
110,645,000
125,530,000
132,211,000
160,531,000
188,611,000
210,558,000
242,902,000
254,440,000
246,481,000
250,126,000
241,526,000
212,680,000
188,496,000
138,774,000
100,755,000
78,224,000
60,579,000
47,017,000
36,559,000
31,279,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.